Risankizumab: 14 agencies, 2019–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia) has been easier on risankizumab than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
Assessment has run over 6.8 years, from 17 Jun 2019 at TLV (Sweden) to 2 Apr 2026 at AOTMIT (Poland).
NICE (England) changed its position: restricted on 21 Aug 2019, recommended by 22 Aug 2024.
Every one of the eight highest-volume agencies in this archive has a record for risankizumab.
Not every gap is a refusal: for risankizumab, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 26 of 56 records date from 2023 or later.
The programme is broad: 14 distinct indication wordings are recorded for risankizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
10 of these 56 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess risankizumab, on 17 Jun 2019; ZIN (Netherlands) did not open a file until 19 Dec 2024 — a wide spread of 5.5 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 8 years in total.
12 of the 14 agencies here assessed risankizumab more than once, PBAC (Australia) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
risankizumab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for risankizumab reads 31 recommended, 11 restricted, 5 not recommended and 2 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 2 Apr 2026 | programu lekowego B.32. „Leczenie pacjentów z chorobą Leśniowskiego-Crohna (ICD-10: K50) | recommended conditionally | source |
| HAS (France) | 10 Dec 2025 | Indication extension | SMR insufficient · ASMR V | source |
| DMC (Denmark) | 3 Sep 2025 | Behandling af voksne patienter med moderat til svær aktiv colitis ulcerosa, der har udvist utilstrækkeligt respons, mist… | Direkte indplacering | source |
| G-BA (Germany) | 20 Feb 2025 | Skyrizi — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 29 Jan 2025 | Indicación terapéutica autorizada: Enfermedad de Crohn Skyrizi está indicado para el tratamiento de pacientes adultos co… | financed by the SNS, on appeal | source |
51 further decisions for risankizumab, across 14 agencies, are not shown here. They include the most recent record on file, 2 Apr 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 36 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 56 decisions for risankizumab from 14 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.